Shareholding disclosure

Newron Pharmaceuticals SpA

Declared position

9.246%

Threshold

Crossed downwards

Timeline

Published

07.02.2025

Transaction

05.02.2025

Voting rights breakdown

Voting rights acquired0%

Voting rights sold9.246%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000PP54

Beneficial owner

Newron Pharmaceuticals SpA

Declared address

NEWRON PHARMACEUTICALS SPA, BRESSO (MILANO), IT

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A.07.02.2025ZA01-000000000PP54

Disclosure summary

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A. on the disposal side, published by SIX Exchange Regulation on 07.02.2025, at 9.246% of voting rights. Notice category: Single shareholder.

Disclosed position

9.246%

Voting rights sold

Voting rights acquired0%

Voting rights sold9.246%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A., published on 07.02.2025.

Publication date07.02.2025

Transaction date05.02.2025

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerNewron Pharmaceuticals SpA

Declared addressNEWRON PHARMACEUTICALS SPA, BRESSO (MILANO), IT

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold9.246%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000PP54

Source: SIX Exchange Regulation · Publication date: 07.02.2025

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open